Literature DB >> 11861292

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Fenghuang Zhan1, Johanna Hardin, Bob Kordsmeier, Klaus Bumm, Mingzhong Zheng, Erming Tian, Ralph Sanderson, Yang Yang, Carla Wilson, Maurizio Zangari, Elias Anaissie, Christopher Morris, Firas Muwalla, Frits van Rhee, Athanasios Fassas, John Crowley, Guido Tricot, Bart Barlogie, John Shaughnessy.   

Abstract

Bone marrow plasma cells (PCs) from 74 patients with newly diagnosed multiple myeloma (MM), 5 with monoclonal gammopathy of undetermined significance (MGUS), and 31 healthy volunteers (normal PCs) were purified by CD138(+) selection. Gene expression of purified PCs and 7 MM cell lines were profiled using high-density oligonucleotide microarrays interrogating about 6800 genes. On hierarchical clustering analysis, normal and MM PCs were differentiated and 4 distinct subgroups of MM (MM1, MM2, MM3, and MM4) were identified. The expression pattern of MM1 was similar to normal PCs and MGUS, whereas MM4 was similar to MM cell lines. Clinical parameters linked to poor prognosis, abnormal karyotype (P =.002) and high serum beta(2)-microglobulin levels (P =.0005), were most prevalent in MM4. Also, genes involved in DNA metabolism and cell cycle control were overexpressed in a comparison of MM1 and MM4. In addition, using chi(2) and Wilcoxon rank sum tests, 120 novel candidate disease genes were identified that discriminate normal and malignant PCs (P <.0001); many are involved in adhesion, apoptosis, cell cycle, drug resistance, growth arrest, oncogenesis, signaling, and transcription. A total of 156 genes, including FGFR3 and CCND1, exhibited highly elevated ("spiked") expression in at least 4 of the 74 MM cases (range, 4-25 spikes). Elevated expression of these 2 genes was caused by the translocation t(4;14)(p16;q32) or t(11;14)(q13;q32). Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861292     DOI: 10.1182/blood.v99.5.1745

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  206 in total

1.  Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.

Authors:  Jason LeGrand; Eun Sung Park; Hongyang Wang; Shalu Gupta; James D Owens; Patrick J Nelson; Wendy DuBois; Thomas Bair; Siegfried Janz; J Frederic Mushinski
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

3.  Identification of genetic networks.

Authors:  Momiao Xiong; Jun Li; Xiangzhong Fang
Journal:  Genetics       Date:  2004-02       Impact factor: 4.562

4.  Prediction of cytogenetic abnormalities with gene expression profiles.

Authors:  Yiming Zhou; Qing Zhang; Owen Stephens; Christoph J Heuck; Erming Tian; Jeffrey R Sawyer; Marie-Astrid Cartron-Mizeracki; Pingping Qu; Jason Keller; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

5.  Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

Authors:  Amberly Moreno-Bost; Susann Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Journal:  Cytotherapy       Date:  2010-12-20       Impact factor: 5.414

6.  Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.

Authors:  Xin Li; Angela Pennisi; Fenghuang Zhan; Jeffrey R Sawyer; John D Shaughnessy; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

7.  Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma.

Authors:  Stavroula Baritaki; Sara Huerta-Yepez; Ma da Lourdas Cabrava-Haimandez; Marialuisa Sensi; Silvana Canevari; Massimo Libra; Manuel Penichet; Haiming Chen; James R Berenson; Benjamin Bonavida
Journal:  For Immunopathol Dis Therap       Date:  2011-04-01

8.  Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Authors:  Lucía López-Corral; Luis Antonio Corchete; María Eugenia Sarasquete; María Victoria Mateos; Ramón García-Sanz; Encarna Fermiñán; Juan-José Lahuerta; Joan Bladé; Albert Oriol; Ana Isabel Teruel; María Luz Martino; José Hernández; Jesús María Hernández-Rivas; Francisco Javier Burguillo; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

9.  The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

Authors:  Karin Tarte; Michel Jourdan; Jean Luc Veyrune; Ingolf Berberich; Geneviève Fiol; Nicole Redal; John Shaughnessy; Bernard Klein
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

10.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.